Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Inventory (2016 - 2025)

Dexcom (DXCM) has disclosed Inventory for 16 consecutive years, with $629.1 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 15.94% to $629.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $629.1 million through Dec 2025, up 15.94% year-over-year, with the annual reading at $629.1 million for FY2025, 15.94% up from the prior year.
  • Inventory for Q4 2025 was $629.1 million at Dexcom, up from $604.1 million in the prior quarter.
  • The five-year high for Inventory was $629.1 million in Q4 2025, with the low at $289.7 million in Q1 2021.
  • Average Inventory over 5 years is $454.6 million, with a median of $459.8 million recorded in 2023.
  • The sharpest move saw Inventory soared 104.16% in 2021, then fell 14.16% in 2022.
  • Over 5 years, Inventory stood at $357.3 million in 2021, then decreased by 14.16% to $306.7 million in 2022, then skyrocketed by 82.46% to $559.6 million in 2023, then decreased by 3.04% to $542.6 million in 2024, then grew by 15.94% to $629.1 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $629.1 million, $604.1 million, and $570.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.